<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03284255</url>
  </required_header>
  <id_info>
    <org_study_id>BXA2017001</org_study_id>
    <nct_id>NCT03284255</nct_id>
  </id_info>
  <brief_title>Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study</brief_title>
  <official_title>A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bio-heart Biological Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CCRF Inc., Beijing, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Bio-heart Biological Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Bioheart Randomized Controlled Trial is a prospective multicentred paralleled study,&#xD;
      which will enroll 430 patients and randomized 1:1 to study group and control group. Aim to&#xD;
      assess the efficacy and safety of Rapamycin Drug-Eluting Bioresorbable Coronary Stent System&#xD;
      compare with XIENCE stent in the treatment of patients with up to two coronary lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multicentred randomized controlled trial, planning to enroll 430&#xD;
      subjects and randomize 1:1 to study group and control group.&#xD;
&#xD;
      All subjects will accept clinical evaluation at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5&#xD;
      year post procedure.&#xD;
&#xD;
      All subjects will accept angiographic evaluation at 1 year post procedure, and simutaneously&#xD;
      80 subjects (40 in study group and 40 in control group) will accepted OCT evaluation.&#xD;
&#xD;
      To assess the efficacy and safety, the primary endpoint will be in segment late luminal loss&#xD;
      at 1 year post procedure, the secondary endpoint is neointima coverage percentage of stent&#xD;
      strut (%) at 1 year post procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in segment late luminal loss</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) from post-procedure to 1 year by angiography，in segment is defined within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neointima coverage percentage of stent strut (%)</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>only in OCT subgroup</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success</measure>
    <time_frame>immediately post procedure</time_frame>
    <description>defined as attainment of residual stenosis less than 30% by visual estimation and TIMI flow grade 3 post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lesion success</measure>
    <time_frame>immediately post procedure</time_frame>
    <description>defined as attainment of diameter residual stenosis less than 30% by visual estimation and TIMI flow grade 3, after the target lesion treated by any PCI methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical success</measure>
    <time_frame>at 1 month post procedure</time_frame>
    <description>defined as attainment of lesion success and without any major adverse cardiac events during hospitalization (up to 7 days after proceduce)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device oriented composite endpoint (DoCE)/target lesion failure (TLF)</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>defined as Cardiac Death, target vessel - myocardial infarction (TV-MI), and ischemic driven - target lesion revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient oriented composite endpoint (PoCE)</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>defined as all caused death, any myocardial infarction, and any revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>cardiac death, vascular death, non-cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction (MI)</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>target vessel MI, non-target vessel MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>ischemic driven, non-ischemic driven</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>ischemic driven, non-ischemic driven</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any coronary revascularization</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC--defined stent thrombosis</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>timing (acute, subacute, late and very late stent thrombosis); relationship (definite, probable and possible stent thrombosis)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>angiographic endpoints-acute stent recoil</measure>
    <time_frame>immediately post procedure</time_frame>
    <description>assess in milimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-late lumen loss (LLL)</measure>
    <time_frame>immediately and 1 year post procedure</time_frame>
    <description>include in stent, 5mm proximal and distal to the stent；</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-minimal lumen diameter (MLD)</measure>
    <time_frame>immediately and 1 year post procedure</time_frame>
    <description>include in stent, 5mm proximal and distal to the stent and in segment；</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-diameter stenosis (DS),</measure>
    <time_frame>immediately and 1 year post procedure</time_frame>
    <description>assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment；</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-angiographic binary restenosis (ABR),</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment.</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Neointimal tissue thickness</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in millimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-late acquired stent malapposition</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in millimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Volume obstruction percentage</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Late stent recoil</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess both in percentage and square millimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Neointimal Healing Score</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>will be calculated by OCT imaging software</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">431</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Antineoplastic Agents</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>study group</intervention_name>
    <description>study group in which patient will accept the treatment of Bioresorbable Coronary Stent</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        subjects that participate in this study must fulfill all the following criteria:&#xD;
&#xD;
        general inclusion criteria:&#xD;
&#xD;
          1. Age from 18 to 75 years old, man or non-pregnant woman;&#xD;
&#xD;
          2. Subjects with asymptomatic ischemic evidence, stable or unstable angina, or old&#xD;
             myocardial infarction, suitable for selective PCI;&#xD;
&#xD;
          3. Subjects without contraindications of coronary artery bypass grafting (CABG);&#xD;
&#xD;
          4. Subjects are able to understand the purpose of this study, volunteer to participate&#xD;
             and sign informed consent, willing to accept invasive imaging follow-up.&#xD;
&#xD;
        Angiographic inclusion criteria:&#xD;
&#xD;
          1. One or two de novo target lesions&#xD;
&#xD;
               1. If subject has only one target lesion, the second non-target lesion can be&#xD;
                  treated but this non-target lesion must locate in a different epicardial vessel,&#xD;
                  and must be treated first and be treated successfully prior to the subjects'&#xD;
                  randomization.&#xD;
&#xD;
               2. If there are two target lesions, they must locate in different epicardial vessels&#xD;
                  and both satisfy the angiographic eligibility criteria.&#xD;
&#xD;
               3. The definition of epicardial vessels means the left anterior descending artery&#xD;
                  (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and&#xD;
                  their branches. Thus, for example, the subject must not have lesions requiring&#xD;
                  treatment in both the LAD and a diagonal branch&#xD;
&#xD;
          2. Target lesion diameter stenosis ≥ 70% (or ≥ 50% simultaneously shall have clinical&#xD;
             evidence of myocardial ischemia), and TIMI flow grade ≥1; Target lesion length ≤24mm&#xD;
             (visually); target lesion diameter between ≥ 2.5 mm to ≤ 4.00 mm.&#xD;
&#xD;
          3. Each target lesion can be fully covered by one stent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If subjects fulfill any of below criterias, this subject shall be exclude from this study.&#xD;
&#xD;
        general exclusion criteria:&#xD;
&#xD;
          1. Any newly onset acute myocardial infarction within 1 week or, myocardial enzymes does&#xD;
             not return to normal level after myocardial infarction;&#xD;
&#xD;
          2. Target lesion has any stents implant history within 1 year or subjects planning to&#xD;
             receive percutaneous artery intervention within half one year;&#xD;
&#xD;
          3. Subjects with severe heart failure (≥ grade III NYHA) or left ventricular ejection&#xD;
             fraction &lt;35% (accessed by ultrasound or left ventricular angiography)&#xD;
&#xD;
          4. Preprocedure severe kidney functional damaged: serum creatinine&gt; 2.0mg /dl (176.8μmol&#xD;
             / L) or subject is receiving hemodialysis;&#xD;
&#xD;
          5. Subjects with bleeding tendency, active gastrointestinal ulcers, history of cerebral&#xD;
             hemorrhage or history of subarachnoid hemorrhage, history within six months of&#xD;
             ischemic stroke, contraindications of anti-platelet agents and anticoagulants&#xD;
             treatment, and subjects cannot receive anti-thrombolytic therapy;&#xD;
&#xD;
          6. Hypersensitive or allergic to aspirin, clopidogrel, heparin, contrast agent,&#xD;
             polylactic acid polymer， rapamycin;&#xD;
&#xD;
          7. The subject's life expectancy is less than 24 months;&#xD;
&#xD;
          8. Subjects participated in other drug or medical device clinical trial and have not&#xD;
             reach the primary endpoint;&#xD;
&#xD;
          9. Investigators determine the subjects' compliance is poor, cannot complete the study as&#xD;
             required;&#xD;
&#xD;
         10. Subjects have accepted substantial organ transplant or ready to undergo organ&#xD;
             transplant;&#xD;
&#xD;
         11. Subjects have unstable arrhythmia, such as high-risk ventricular premature beats, and&#xD;
             ventricular tachycardia;&#xD;
&#xD;
         12. Subjects need to receive chemotherapy because of tumor;&#xD;
&#xD;
         13. Subjects have received or planning to receive coronary or chest radiotherapy;&#xD;
&#xD;
         14. Subjects with Immunosuppressive, autoimmune diseases, are planned or undergoing&#xD;
             immunosuppressive therapy;&#xD;
&#xD;
         15. Subjects are planning to receive or are receiving long-term anticoagulation therapy,&#xD;
             such as heparin, warfarin and so on;&#xD;
&#xD;
         16. Subjects are planning to accept selective surgery within 6 months, need to discontinue&#xD;
             aspirin or clopidogrel;&#xD;
&#xD;
         17. Blood tests showed that the platelet count is less than 100 × 109 / L, or over than&#xD;
             700 × 109 / L, the white blood cells count is less than 3 × 109 / L;&#xD;
&#xD;
         18. Diagnosed or suspected liver disease (such as hepatic cirrhosis);&#xD;
&#xD;
         19. Subjects with diffuse peripheral vascular disease, cannot use 6F catheter.&#xD;
&#xD;
        angiographic exclusion criteria&#xD;
&#xD;
        these exclusion criteria apply to the target or non-target lesion(s), target or non-target&#xD;
        vessel(s)&#xD;
&#xD;
          1. Target or non-target lesion(s) located in left main;&#xD;
&#xD;
          2. Subjects with coronary artery triple vessel lesion in LAD, LCX or RCA, all need to be&#xD;
             treated.&#xD;
&#xD;
        these exclusion criteria apply to the target lesion(s) or target vessel(s)&#xD;
&#xD;
          1. Target lesion located in left main;&#xD;
&#xD;
          2. Target lesion located in the aorto-ostial of RCA (within 3 mm of the origin of the&#xD;
             RCA);&#xD;
&#xD;
          3. Target lesion located within 3 mm of the origin of the LAD and LCX;&#xD;
&#xD;
          4. Lesion involving a bifurcation with a:&#xD;
&#xD;
               1. Side branch ≥ 2.5 mm in diameter, or&#xD;
&#xD;
               2. Side branch with diameter stenosis ≥ 50%, or&#xD;
&#xD;
               3. Side branch requiring protection guide wire, or&#xD;
&#xD;
               4. Side branch requiring pre-dilatation.&#xD;
&#xD;
          5. Anatomy proximal to or within the lesion that may affect delivery of the Bioheart or&#xD;
             XIENCE stent, including:&#xD;
&#xD;
               1. Extreme angulation (≥ 90°) proximal to or within the target lesion, or&#xD;
&#xD;
               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion,&#xD;
                  or&#xD;
&#xD;
               3. Moderate or heavy calcification proximal to or within the target lesion&#xD;
&#xD;
          6. Target lesion involves a myocardial bridge.&#xD;
&#xD;
          7. Target vessel contains thrombus as indicated in the angiographic images or IVUS.&#xD;
&#xD;
          8. Prior to the index procedure target vessel has been previously treated with a stent at&#xD;
             any time such that the Bioheart or XIENCE stent would need to cross the stent to reach&#xD;
             the target lesion.&#xD;
&#xD;
          9. Target vessel has been previously treated with a stent and the target lesion is within&#xD;
             5 mm proximal to a previously treated lesion.&#xD;
&#xD;
         10. Target lesion cannot reach the following outcomes, after the complete balloon&#xD;
             pre-dilatation:&#xD;
&#xD;
               1. Residual (DS %) is &lt; 40% (per visual estimation), ≤ 20% is strongly recommended;&#xD;
&#xD;
               2. TIMI Grade-3 flow (per visual estimation);&#xD;
&#xD;
               3. No angiographic complications (e.g., no-reflow, distal embolization, side branch&#xD;
                  closure)&#xD;
&#xD;
               4. No dissections NHLBI grade D-F;&#xD;
&#xD;
               5. No chest pain lasting &gt; 5 minutes, and;&#xD;
&#xD;
               6. No ST depression or elevation lasting &gt; 5 minutes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shubin Qiao, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Xu, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BeijingChao-YangHospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Frist Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Gunagdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangshan Gongren Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaocheng People's Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Dongfang Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital-Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Autonomous Region People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>The Inner Mongolia Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taida International Cardioascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioresorbable Vascular Scaffold System</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Cardiac Catheterization</keyword>
  <keyword>Tomography, Optical Coherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03284255
org study id: BXA2017001
nct id: NCT03284255
lead sponsor: 
collaborator: 
is fda regulated drug: No
is fda regulated device: No
The Bioheart Randomized Controlled Trial is a prospective multicentred paralleled study,
      which will enroll 430 patients and randomized 1:1 to study group and control group. Aim to
      assess the efficacy and safety of Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
      compare with XIENCE stent in the treatment of patients with up to two coronary lesions.
This study is a prospective, multicentred randomized controlled trial, planning to enroll 430
      subjects and randomize 1:1 to study group and control group.

      All subjects will accept clinical evaluation at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5
      year post procedure.

      All subjects will accept angiographic evaluation at 1 year post procedure, and simutaneously
      80 subjects (40 in study group and 40 in control group) will accepted OCT evaluation.

      To assess the efficacy and safety, the primary endpoint will be in segment late luminal loss
      at 1 year post procedure, the secondary endpoint is neointima coverage percentage of stent
      strut (%) at 1 year post procedure.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: in segment late luminal loss
time frame: 1 year post procedure
description: In-segment late loss is defined as the change in minimal lumen diameter (MLD) from post-procedure to 1 year by angiography，in segment is defined within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.
measure: neointima coverage percentage of stent strut (%)
time frame: 1 year post procedure
description: only in OCT subgroup
measure: device success
time frame: immediately post procedure
description: defined as attainment of residual stenosis less than 30% by visual estimation and TIMI flow grade 3 post stent implantation
measure: lesion success
time frame: immediately post procedure
description: defined as attainment of diameter residual stenosis less than 30% by visual estimation and TIMI flow grade 3, after the target lesion treated by any PCI methods
measure: clinical success
time frame: at 1 month post procedure
description: defined as attainment of lesion success and without any major adverse cardiac events during hospitalization (up to 7 days after proceduce)
measure: Device oriented composite endpoint (DoCE)/target lesion failure (TLF)
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
description: defined as Cardiac Death, target vessel - myocardial infarction (TV-MI), and ischemic driven - target lesion revascularization (ID-TLR)
measure: Patient oriented composite endpoint (PoCE)
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
description: defined as all caused death, any myocardial infarction, and any revascularization.
measure: death
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
description: cardiac death, vascular death, non-cardiovascular death
measure: myocardial infarction (MI)
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
description: target vessel MI, non-target vessel MI
measure: target lesion revascularization
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
description: ischemic driven, non-ischemic driven
measure: target vessel revascularization
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
description: ischemic driven, non-ischemic driven
measure: any coronary revascularization
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
measure: ARC--defined stent thrombosis
time frame: at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure
description: timing (acute, subacute, late and very late stent thrombosis); relationship (definite, probable and possible stent thrombosis)
measure: angiographic endpoints-acute stent recoil
time frame: immediately post procedure
description: assess in milimeter
measure: angiographic endpoints-late lumen loss (LLL)
time frame: immediately and 1 year post procedure
description: include in stent, 5mm proximal and distal to the stent；
measure: angiographic endpoints-minimal lumen diameter (MLD)
time frame: immediately and 1 year post procedure
description: include in stent, 5mm proximal and distal to the stent and in segment；
measure: angiographic endpoints-diameter stenosis (DS),
time frame: immediately and 1 year post procedure
description: assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment；
measure: angiographic endpoints-angiographic binary restenosis (ABR),
time frame: 1 year post procedure
description: assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment.
measure: OCT imaging endpoints-Neointimal tissue thickness
time frame: 1 year post procedure
description: assess in millimeter
measure: OCT imaging endpoints-late acquired stent malapposition
time frame: 1 year post procedure
description: assess in millimeter
measure: OCT imaging endpoints-Volume obstruction percentage
time frame: 1 year post procedure
description: assess in percentage
measure: OCT imaging endpoints-Late stent recoil
time frame: 1 year post procedure
description: assess both in percentage and square millimeter
measure: OCT imaging endpoints-Neointimal Healing Score
time frame: 1 year post procedure
description: will be calculated by OCT imaging software
arm group label: study group
arm group type: Experimental
description: in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
arm group label: control group
arm group type: Active Comparator
description: in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
intervention type: Device
intervention name: study group
description: study group in which patient will accept the treatment of Bioresorbable Coronary Stent
arm group label: study group
other name: BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
intervention type: Device
intervention name: control group
description: control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
arm group label: control group
other name: Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Shubin Qiao, professor
role: Principal Investigator
affiliation: Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)
last name: Bo Xu, professor
role: Study Chair
affiliation: Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: China
responsible party type: Sponsor
mesh term: Coronary Artery Disease
mesh term: Myocardial Ischemia
mesh term: Coronary Disease
sharing ipd: Undecided